share_log

Morgan Stanley Upgrades PTC Therapeutics to Equal-Weight, Raises Price Target to $30

Morgan Stanley Upgrades PTC Therapeutics to Equal-Weight, Raises Price Target to $30

摩根士丹利将PTC Therapeutics上调至同等权重,将目标股价上调至30美元
Benzinga ·  04/29 05:11

Morgan Stanley analyst Jeffrey Hung upgrades PTC Therapeutics (NASDAQ:PTCT) from Underweight to Equal-Weight and raises the price target from $28 to $30.

摩根士丹利分析师洪杰弗里将PTC Therapeutics(纳斯达克股票代码:PTCT)从 “减持” 上调至 “等持”,并将目标股价从28美元上调至30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发